JP2013535220A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535220A5
JP2013535220A5 JP2013524130A JP2013524130A JP2013535220A5 JP 2013535220 A5 JP2013535220 A5 JP 2013535220A5 JP 2013524130 A JP2013524130 A JP 2013524130A JP 2013524130 A JP2013524130 A JP 2013524130A JP 2013535220 A5 JP2013535220 A5 JP 2013535220A5
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
preparing
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013524130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535220A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/046797 external-priority patent/WO2012019123A1/en
Publication of JP2013535220A publication Critical patent/JP2013535220A/ja
Publication of JP2013535220A5 publication Critical patent/JP2013535220A5/ja
Ceased legal-status Critical Current

Links

JP2013524130A 2010-08-06 2011-08-05 ツブリシンを調製するためのプロセス Ceased JP2013535220A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37143310P 2010-08-06 2010-08-06
US61/371,433 2010-08-06
PCT/US2011/046797 WO2012019123A1 (en) 2010-08-06 2011-08-05 Processes for preparing tubulysins

Publications (2)

Publication Number Publication Date
JP2013535220A JP2013535220A (ja) 2013-09-12
JP2013535220A5 true JP2013535220A5 (enExample) 2014-10-16

Family

ID=45559842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524130A Ceased JP2013535220A (ja) 2010-08-06 2011-08-05 ツブリシンを調製するためのプロセス

Country Status (12)

Country Link
US (3) US8889880B2 (enExample)
EP (1) EP2600866A4 (enExample)
JP (1) JP2013535220A (enExample)
KR (1) KR20130096712A (enExample)
CN (1) CN103140227B (enExample)
AU (1) AU2011285532B2 (enExample)
BR (1) BR112013003004A2 (enExample)
CA (1) CA2807511A1 (enExample)
EA (1) EA025471B1 (enExample)
MX (1) MX2013001402A (enExample)
SG (1) SG187728A1 (enExample)
WO (1) WO2012019123A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN101678124A (zh) 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
EP2600866A4 (en) * 2010-08-06 2013-12-11 Endocyte Inc PROCESS FOR THE PRODUCTION OF TUBULYSINES
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) * 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
MY171561A (en) 2012-11-15 2019-10-18 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
CN106132959B (zh) * 2014-01-28 2020-04-17 管道制药有限责任公司 用于缀合的细胞毒性微管溶素化合物
ES2819863T3 (es) 2014-04-11 2021-04-19 Medimmune Llc Anticuerpos contra HER2 biespecíficos
CA2962783A1 (en) 2014-10-01 2016-04-07 Medimmune, Llc Method of conjugating a polypeptide
KR20170137725A (ko) * 2015-02-25 2017-12-13 윌리엄 마쉬 라이스 유니버시티 데스아세톡시투불리신 h 및 이의 유사체
SG10202103712VA (en) 2015-11-10 2021-05-28 Medimmune Llc Binding molecules specific for asct2 and uses thereof
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017132298A1 (en) 2016-01-27 2017-08-03 Medimmune, Llc Methods for preparing antibodies with a defined glycosylation pattern
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的b7-h3-結合分子、其抗體藥物綴合物及其使用方法
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
JP7150820B2 (ja) 2017-08-01 2022-10-11 メディミューン,エルエルシー Bcmaモノクローナル抗体薬剤コンジュゲート
US11274124B2 (en) 2017-11-29 2022-03-15 William Marsh Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
US11795225B2 (en) 2020-09-11 2023-10-24 Medimmune Limited Therapeutic binding molecules
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
EP4429765A1 (en) 2021-11-10 2024-09-18 Astrazeneca AB Antibody molecules and conjugates
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
MX2024010956A (es) 2022-03-09 2024-09-17 Astrazeneca Ab Moleculas de union contra fra.
MA71241A (fr) 2022-06-27 2025-04-30 Astrazeneca Ab Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
EP1523493B1 (de) 2002-07-09 2013-09-04 Dömling, Alexander Neue tubulysinanaloga
WO2004005326A2 (de) 2002-07-09 2004-01-15 Morphochem Aktiengellschaft Fu Tubulysinkonjugate
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CN101678124A (zh) 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
DE102009032972A1 (de) 2009-07-14 2011-01-20 Erbe Elektromedizin Gmbh Vorrichtung zur Herstellung von Anastomosen
WO2011069116A1 (en) 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US20120322741A1 (en) 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2600866A4 (en) * 2010-08-06 2013-12-11 Endocyte Inc PROCESS FOR THE PRODUCTION OF TUBULYSINES

Similar Documents

Publication Publication Date Title
JP2013535220A5 (enExample)
JP2014043462A5 (enExample)
JP2012526842A5 (enExample)
JP2010510976A5 (enExample)
UA109883C2 (uk) Спосіб отримання сполук для застосування як інгібіторів sglt2
EP4282482A3 (en) Nucleoside phosphoramidate prodrugs
EP4328223A3 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
JP2009143956A5 (enExample)
EP3051350A3 (en) Alcoholic compound and method for producing alcoholic compound
CA2796872A1 (en) Novel synthesis for thiazolidinedione compounds
EP4230631A3 (en) Process for making trisubstituted silyloxyethyl triflates
JP2018502077A5 (enExample)
EP3388426A3 (en) Compounds for protection of cells
JP2016537382A5 (enExample)
MX352470B (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
RU2017144050A (ru) Способ синтеза производных рапамицина
RU2012128887A (ru) Способ получения гидрохлорида моксифлоксацина и его промежуточных продуктов
JP2016513100A5 (ja) フルオロスルホナートエステルまたはその塩を調整する方法
JP2011526896A5 (enExample)
JP2012503653A5 (enExample)
JP2008517965A5 (enExample)
JP2013522207A5 (enExample)
JP2013527149A5 (enExample)
JP2013506703A5 (enExample)
CA2554070A1 (en) Macrolides with antiinflammatory activity